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Abstract
Background: Muscular dystrophies are chronic diseases manifesting with progressive muscle
weakness leading to decreasing activities and participation. To understand the impact on daily life,
it is important to determine patients' quality of life.
Objective: To investigate Health Related Quality of Life (HRQoL) of children and adults with
muscular dystrophy (MD), and to study the influence of type and severity of MD on HRQoL in adult
patients.
Methods: Age-related HRQoL questionnaires were administered to 40 children (8–17 years), and
67 adult patients with muscular dystrophies.
Results: Significant differences in HRQoL were found in children and adults with MD compared
to healthy controls. Patients with Becker muscular dystrophy reported a better HRQoL on the
several scales compared to patients with other MDs. Severity was associated with worse fine
motor functioning and social functioning in adult patients.
Conclusion: This is one of the first studies describing HRQoL of patients with MD using validated
instruments in different age groups. The results indicate that having MD negatively influences the
HRQoL on several domains.
Background
Duchenne muscular dystrophy (DMD) is the most fre-
quent muscular dystrophy of childhood [1]. Disease pro-
gression is severe, leading to loss of ambulation around
the age of 10 and respiratory insufficiency necessitating
night-time ventilatory support around the age of 20 years
[1]. Becker muscular dystrophy (BMD) runs a more varia-
ble and usually more benign course. Sarcoglycanopathies
(limb girdle muscular dystrophies (LGMD) 2C-F), can
have a DMD or BMD like course [2]. Cardiac involvement
can be prominent in these disorders [3,4]. LGMD2A usu-
ally starts in childhood and leads to loss of ambulation
around the fourth decade. No cardiac involvement is
encountered in this disorder [2]. Both dystrophinopathies
and limb girdle muscular dystrophies are chronic and pro-
gressive diseases which lead to decreasing activities and
participation. Patients will have to learn to cope with
declining motor abilities, which influence their quality of
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life (QoL). QoL is a multidimensional structure and con-
tains generally three general domains: physical, psycho-
logical and social functioning of a patient [5]. In the study
of Bothwell [6] it was shown that families with a son diag-
nosed with DMD considered QoL as more important
above physical functioning. In addition, various studies
have shown that healthcare professionals underestimate
the QoL of their patients, which may affect the level of
care the patients receive [7,8].
QoL has been studied mostly in end of life care issues [6-
8]. Some studies have been performed to identify the
manner in which individuals with MD perceive their QoL
in their current living situation, but many studies lack the
administration of standardized QoL instruments. An
example is a recent study by Rahbek et al. [9] in which
adults with DMD were interviewed. They conclude that
the patients report their quality of life to be excellent.
Problems were reported in the area of qualifying educa-
tion, love life and pain. Several others report negative con-
sequences in the areas of occupation, energy or emotional
experiences [10,11]. QoL has been objective of many
studies among patients with chronic diseases, in which
health status, i.e. the possibility of an individual to per-
form his daily activities and to fulfil his needs, has been
the major perspective. Functional health and Health
Related QoL are often used as outcome measures to eval-
uate patient's well being. The terms are often mixed up in
literature. Functional health is defined as an individual's
ability to perform normal daily activities, essential in
order to meet basic needs, to fulfil usual roles, and to
maintain health and well-being. Quality of life (QoL) is
defined as an individual's perception of their position in
life, in the context of the culture and value systems in
which they live, and in relation to their goals, expecta-
tions, standards and concerns. HRQoL is defined as QoL
in which a dimension of personal judgement over one's
health and disease is added. [12] In case of children
(HR)QoL is influenced also by factors such as the ability
to participate in peer groups and the ability to keep up
with developmental activities. Furthermore, it is impor-
tant not to rate health problems only, but also to include
the impact of these problems as perceived by the person
involved. Such studies have not been done often yet.
Measurement in children requires age-adjusted question-
naires because children need adequate language skills and
the cognitive ability to interpret the questions. Unfortu-
nately reliable and valid translated HRQoL instruments
are still scarce in the pediatric field [12]. Consequently,
parents usually function as the major informants in pedi-
atric assessments, especially in young children. However,
self-reported quality of life is considered as most inform-
ative and important [12].
The present study aimed to answer the following three
questions: (1) Does HRQoL of children with MD, meas-
ured with self-reports, differ from that of a group of
healthy children? (2) Does the HRQoL of adults with MD
differ from that of a group of healthy controls? (3) Are
type of MD and severity predictors of HRQoL of adults
with MD? Based on previous research with children and
adults with chronic diseases we hypothesize that HRQoL
will be affected on all domains.
Methods
Participants
Between 2001 and May 2005 patients with Duchenne
muscular dystrophy, Becker muscular dystrophy, female
carriers of both diseases and patients with a sarcoglycano-
pathy were asked to participate in an ungoing study. Ter-
tiary Dutch neuromuscular referral centres in academic
hospitals or rehabilitation centres contacted most
patients. Inclusion criteria for eligibility were the follow-
ing: age 8 to 80 years, genetic confirmation of DMD,
BMD, carriership or sarcoglycanopathy by DNA analysis
or muscle biopsy demonstrating absent, reduced or
abnormal dystrophin or sarcogycan on immunohisto-
chemical and/or immunobiochemical analysis. Carriers
were considered symptomatic when symptoms attributa-
ble to skeletal muscles, like cramps or muscle weakness,
were present. Patients or carriers who recently had a cardi-
ovascular event or underwent a major surgical interven-
tion were excluded. For the present study we approached
patients from our own clinic who were included between
May 2002 and May 2003. In addition, calpainopathy
(LGMD2A) patients who were identified in our large
LGMD survey and in whom mutations in the calpain-3
gene were demonstrated [13] were asked for their cooper-
ation. All patients received an introduction letter, in
which the aim of the study was explained and participa-
tion was requested. After permission was given, data were
collected with questionnaires. The interviews were mostly
done by phone. Some were done in the hospital or in the
patients' home. All interviews, with both pediatric as well
as adult patients, were done by one medical student (JB).
In all cases, the interviewer read out aloud the question
and all possible answers and subsequently, the patient
could choose one of the answers. In case of pediatric
patients, parents were asked to leave to room to give the
child the opportunity to answer questions openly. At the
end of the interview the patient was encouraged to give
his/her comment on the questionnaire. Several clinical
characteristics were extracted from the medical files,
including type of diagnosis, severity of disease and the
child's intelligence. In the adult population type and
severity of muscle dystrophy were determined. Severity
was judged with Brooke's scale, a functional index for use
of legs and hip muscles (ranging from 1 = walking and
climbing stairs without help to 10 = bedridden). The cutHealth and Quality of Life Outcomes 2007, 5:31 http://www.hqlo.com/content/5/1/31
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off value for severity (yes/no) in adults was the loss of
independent walking (Brooke score ≥ 5) [13,14].
Instruments
The Dutch Institute of Prevention and Health and the Lei-
den University Hospital (TNO-AZL) designed question-
naires for measuring HRQoL for different age groups: the
TNO-AZL Children's Quality of Life questionnaire (TAC-
QoL) for children ages 6–15 years [15-18], and the TNO-
AZL Adult Quality of Life questionnaire (TAAQoL) for 16
years and older [19]. These questionnaires are generic
Dutch instruments that measure health status problems
weighted by the impact of the health status problems on
well-being. It offers the respondent the possibility of dif-
ferentiating between their functioning and the way they
feel about it. Most of the items consist of two questions
linked to one another. On the first one the respondent can
rate whether or not a specific problem occurred in the past
few weeks. The second one is about the possible negative
emotional responses to the problems. The respondent can
indicate how he felt about this problem on a four point
Likert scale: fine – not so good – quite bad – bad. The
items are clustered into multi-item scales with higher
scores indicating higher quality of life.
TACQOL: children
The TACQoL was developed and validated in a large sam-
ple of Dutch school-going children aged 8–15 years,
including children with or without a chronic medical con-
dition [17,18]. Data were collected in twelve municipal
health services located throughout the Netherlands. The
TACQOL assesses functioning of children aged 8–15 years
with the Child-Form (CF). The instrument contains seven
scales of eight items each: physical functioning (e.g. the
child is experiencing stomach-aches or abdominal pain,
feeling sleepy), autonomy (e.g. is having difficulties going
to school alone, or doing hobbies independently), motor
functioning (e.g. problems running, or with balance),
cognitive functioning (e.g. difficulties paying attention or
concentrating, difficulty writing) and social functioning
(e.g. impaired ability to play or talk with other children,
or to feel at ease with other children), positive emotions
(e.g. feelings of joy or contentedness) and negative emo-
tions (e.g. sadness or aggression). A concretely and specif-
ically formulated health status problem, if reported, leads
to a question about the emotional response. Figure 1
shows an example of such a question. On each item of the
first five domains the respondent indicates the extend to
which a specific problem occurred in the past few weeks
(never (4) – sometimes- often). If a problem occurred, the
child can indicate how he/she felt about this problem on
a four point Likert scale: (very) good (3) – not so well (2)
– rather bad (1) – bad (0.) The emotional reaction to the
complaints represents the 'Health-Related' component,
which is reported here. Scores for these domains range
from 0–32. On the domains regarding positive and nega-
tive emotions, respondents can indicate on a three-point
Likert scale whether the presented feelings were present in
recent weeks (never (2)-occasionally (1) -often (0)).
Scores on these two domains range from 0–16. Numbers
between brackets in Figure 1 refer to the values resulting
in the HRQoL scores. It takes approximately 15–20 min-
utes to fill in the questionnaire. In the calculation of the
scale scores one or two missing combined-item scores are
allowed for. They are replaced by the mean value of the
non-missing (combined-) item scores. For respondents
with more missing combined item scores per scale, the
scale score is assumed to be missing.
Scale structure and reliability proved less satisfactory for
the older children between 12–15 years. Therefore it was
advised to adapt the scale structure for the older children
by removing some items for the original social scale and
one scale in its totality (autonomy). Since children with
chronic diseases are treated by the pediatrician until the
age of 18, patients in our population aged 15–17 years
were also administered the TACQoL-CF.
TAAQoL: adults
The TAAQoL [19] is a multidimensional instrument, with
12 scales: gross motor functioning (e.g. difficulty walking,
bending), fine motor functioning (e.g. difficulty cutting
papers or opening a can), cognitive functioning (e.g. diffi-
culty remembering or concentrating), sleep (e.g. sleeping
restlessly, lay awake a lot), pain (e.g. back-ache, pain in
neck-shoulders), social functioning (e.g. talk to others;
visit friends), limitations of daily activities (e.g. difficulties
with work; done less work), sexual functioning (e.g. had
less sex), vitality (e.g. feel energetic; tired), happiness (e.g.
feel joyful; cheerful), depressive moods (e.g. feel sad or
worried) and aggressiveness (e.g. feel angry; aggressive).
In all scales, except in the scales concerning sexual func-
tioning (two questions) and aggressiveness (3 questions),
each scale consists of four questions. It takes approxi-
mately 10–20 minutes to fill in the questionnaire. For the
TAAQoL, the scale scores are obtained by adding item
scores within scales and transforming crude scale scores to
a 0–100 scale. In the calculation of the scale scores one
missing combined-item score per scale is allowed for. A
missing item score is replaced by the mean value of the
non-missing (combined-) item scores. For respondents
An example of a TACQol-CF question translated from the  Dutch original Figure 1
An example of a TACQol-CF question translated from the 
Dutch original.
Have you had difficulty 
running?  never (4)   sometimes   often 
~
During this, I felt: 
 (very) good 
(3)
 not so well (2)   rather bad (1)   bad  
(0) Health and Quality of Life Outcomes 2007, 5:31 http://www.hqlo.com/content/5/1/31
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with more missing combined-item scores per scale, the
scale score is assumed to be missing. Patients older than
18 years were administered the TAAQoL. Norm data from
the general Dutch population were available. The refer-
ence study was carried out in two samples of the general
population. Several steps were undertaken to study the
psychometric aspects of the questionnaire. E.g. the con-
vergent validity was assessed by calculating correlation
coefficients with the Dutch versions of the SF-36 and with
the "Psychological complaints-scale" of the Hopkins
Symptom Checklist. Criterion validity was assessed by
testing the differences in scales scores of people with and
without chronic conditions and those who visited a doc-
tor versus those who did not during the last 6 months.
Based on these results it is concluded that the instrument
measure HRQOL on group level in a reliable and valid
way [19].
Statistics
The Statistical Package for Social Sciences (SPSS), Win-
dows version 11.5, was used for all analyses. Before con-
ducting the final analyses several preparation analyses
were conducted. Firstly, scales were constructed and miss-
ing data imputed on the basis of the guidelines of the
questionnaires used. Secondly, the reliability of these
scales was calculated. Thirdly, descriptive statistics were
used to describe the demographic and medical character-
istics of the participants.
Children
Normative data for the TACQoL are presented in two age
groups: children 8 – 11 years old, and adolescents 12 – 15
years. Since the MD population included children ranging
from 8 – 17 years old, it was first tested whether the MD
age group 12–15 years (n = 14) differed from the MD age
group of 16 and 17 years old (n = 7) with respect to
HRQoL. Mann-Whitney U tests revealed HRQoL scales
scores to be similar for the two groups, so in further anal-
yses the two groups were taken together. Thereafter, one-
sample t-tests were used to compare the means on the
TACQoL scales of the children aged 8–11 years with MD
with available norms, and for adolescents with that of
available norm data. The autonomy and social function-
ing scales of children aged 12–15 years were not included
in the analysis due to a low reliability of those scales in
this population. Effect sizes (d) were calculated by divid-
ing the difference in mean score between the patient
group and the norm group by the standard deviation of
the scores in the norm group. Effect sizes give insight into
the magnitude of a difference between independent
groups. According to Cohen effect sizes of up to 0.2 were
considered to be small, effect sizes of about 0.5 to be mod-
erate and effect sizes of about 0.8 to be large [20].
Adults
For the adults with MD, comparisons were made with the
data from the general population (n = 4410) of all ages
using one-sample t-tests, according to gender [19] and
effect sizes were calculated. Differences on all twelve
HRQoL mean scale scores between adults with different
disease types were examined using analyses of variance
(ANOVA) and post-hoc procedures according to Scheffe.
Considering the number of Duchenne patients (n = 4),
they were left out of the comparison on disease type. To
examine differences in HRQoL between adult patients
with different severity independent-samples t-tests were
used.
Considering the explorative nature of the study p-values
of p < 0.05 were considered significant.
Results
Patient characteristics
In total 43 children with a muscular dystrophy were
approached to participate in the study, of these 40 chil-
dren agreed to participate (response rate 93 %). Sixty-
eight adult patients were approached to participate in the
study, and 67 agreed (response rate 99%). Table 1 shows
the characteristics of the participating children and adults.
From the children five were diagnosed with cardiomyop-
athy, and from the adult population nine patients. Not all
the patients were diagnosed yet at the time of participa-
tion in the quality of life study.
HRQoL of children and adolescents with MD
The HRQoL of the children aged 8–11 years with MD
appeared to be significantly worse (p < 0.05) than the
HRQoL of age-matched children from the general Dutch
population, on four out of seven scales of the TACQoL:
motor functioning, social functioning, positive emotions
and autonomy (see Table 2). Surprisingly for physical
Table 1: Socio-demographic and medical characteristics of the 
patients
Children (n = 40) Adults (n = 67)
Age at study (years)
Mean (SD) 12.6 (2.8) 40.7 (13.9)
Range 8–17 18–67
Gender (%)
- male 38 (95) 46 (69)
- female 2 (5) 21 (31)
Age categories (%)
- 6–11 years 18 (45)
- 12–17 years 22 (55)
Type of disease n% n   (less severe/
severe)
%
- Duchenne Muscular 
dystrophy (DMD)
36 90 4 (-/4) 6
- Becker muscular 
dystrophy (BMD)
- 25 (16/9) 37
- Sarcoglycanopathies 
(LGMD2C-F)




Severity: severe = loss of independent walking (Brooke score ≥ 5)Health and Quality of Life Outcomes 2007, 5:31 http://www.hqlo.com/content/5/1/31
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symptoms a better HRQOL was reported by the children.
The differences were moderate for physical symptoms and
large for motor functioning, autonomy, social function-
ing and positive emotions.
Significant differences on the TACQoL-CF between ado-
lescents aged 12–17 years with MD and the norm group
were found for the scales of physical functioning and
motor functioning (see Table 3). Adolescents reported
better physical functioning, but worse motor functioning.
These differences were moderate for physical symptoms
and large for motor functioning.
HRQoL of adults with MD
Table 4 presents the mean scores on all TAAQoL scales of
adults (males and females) with MD in comparison with
TAAQoL scores of the general Dutch population (males
and females). For both male and female patients a signif-
icantly worse HRQoL was found compared to healthy
controls on the scales: gross and fine motor functioning,
daily activities, vitality, and depressive moods. Males also
report problems in the area of pain and aggressiveness,
whereas females report problems for sleeping. Neither
males nor females report problems on the scales of cogni-
tive and sexual functioning and on the scale of happiness.
Surprisingly, a significant difference for females was
found for social functioning. Female patients reported a
better social functioning.
Differences for males were small on the scales of pain and
daily activities, moderate on the scales of aggressiveness,
depressive moods and vitality, and large for gross and fine
motor functioning. Differences for females were moderate
on the scales of daily activities, vitality and depressive
moods, and large for gross and fine motor functioning
and sleeping.
Influence of type and severity of MD in adults on HRQoL
Significant differences on the TAAQoL (Table 5) between
the types of MD were found for fine motor functioning,
sleeping, daily activities, vitality and depressive mood.
Patients with BMD had higher HRQoL scores on fine
motor functioning and sleeping than sarcoglycanopathy
patients, and higher scores on daily activities and depres-
sive moods than calpainopathy patients. Although a sig-
nificant difference was found for vitality with the analysis
of variance, the scheffe-procedure just failed to reach sig-
nificance between groups. Patients with more severe MD
had lower scores for fine motor functioning and social
functioning (Table 6).
Discussion
This is one of the first studies to describe the health related
quality of life (HRQoL) of both children and adults with
different muscular dystrophies (MDs) using validated and
reliable instruments. The results of the present study indi-
cate that having a MD does negatively influence the
HRQoL on several domains, which can be expected
because of obvious reasons.
Children (aged 8–11) reported a worse HRQoL on motor
functioning and autonomy which can be expected consid-
ering the progressive nature of their MD, but they also
reported a worse HRQoL on social functioning and emo-
tional functioning as compared to age-related healthy
individuals. Especially the latter shows that HRQoL of the
patients is affected. The large effect sizes on these two
scales underscore the clinical significance of these find-
ings. Surprisingly, both children and adolescents reported
a better HRQoL for physical symptoms. Considering the
items included on this scale which do not relate to their
disease, it may be that children with MD respond emo-
tionally different to such problems than healthy children.
Living with their progressive disease possible changed
their values, which may be a result of the process of
response shift, which has been described in adults with
Table 3: Mean health-related quality of life scores (TACQoL) for 
adolescents age 12–17 with MD and healthy children
MD healthy children
Mean (SD) Mean (SD)
N = 22 N = 1249 d
Physical symptoms 26.8 (4.4.)** 23.7 (5.4) -0.6
Motor functioning 23.2 (4.4)*** 29.8 (3.3) 2
Cognitive function 28.1 (4.7) 27.6 (4.1) -0.1
Positive emotions 12.9 (2.3) 13.0 (2.8) 0.0
Negative emotions 12.4 (2.3) 11.6 (2.6) -0.3
Higher scores indicate a better quality of life
d = effect size
One sample t-test ** p < 0.01; *** p < 0.00
Table 2: Mean health-related quality of life scores (TACQoL) for 
children age 8–11 with MD and healthy children
Children
MD Healthy children
Mean (SD) Mean (SD)
N = 18 N = 1094 d
Physical symptoms 26.8 (3.0) * 24.9 (5.1) -0.4
Motor functioning 20.4 (6.3) *** 29.8 (3.2) 2.9
Autonomy 23.8 (5.8) *** 31.2 (1.9) 3.8
Cognitive functioning 26.5 (4.5) 28.4 (3.9) 0.5
Social functioning 26.7 (4.5) * 29.7 (2.8) 1.1
Positive emotions 11.2 (3.5) * 13.6 (2.5) 1.0
Negative emotions 11.3 (3.0) 11.6 (2.7) 0.1
Higher scores indicate a better quality of life.
d = effect size
One-sample t-test * p < 0.05; ** p < 0.01; *** p < 0.001Health and Quality of Life Outcomes 2007, 5:31 http://www.hqlo.com/content/5/1/31
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Table 5: Mean health-related quality of life scores for adults patients on the TAAQoL according to type of MD
TAAQOL Types of MD
mean (SD) mean (SD) Mean (SD)
LGMD2C-F BMD LGMD2A
N = 15 N = 25 N = 23
Gross Motor 36.3 (27.0) 34.5 (27.5) 25.3 (21.7)
Fine Motor 71.7 (18.3) 89.3 (20.0)* X 82.9 (16.6)
Cognitive Functioning 76.7 (27.1) 83.5 (22.7) 79.3 (31.0)
Sleeping 42.5 (41.9) 81.0 (28.7) **X 59.8 (37.8)
Pain 59.2 (34.8) 70.8 (19.3) 66.3 (31.9)
Social Functioning 90.4 (18.0) 93.8 (12.1) 85.3 (22.6)
Daily activities 71.3 (32.7) 84.8 (20.6) *∇ 57.9 (38.6)
Sexual functioning 88.5 (20.1) 95.5 (12.5) 78.6 (39.2)
Vitality 39.4 (29.3) 61.0 (19.1) 44.9 (31.9)
Happiness 62.2 (22.9) 72.0 (15.2) 58.7 (23.9)
Aggressiveness 78.5 (24.3) 80.4 (21.6) 73.4 (29.2)
Depressive moods 66.1 (22.2) 80.0 (16.7) *∇ 60.1 (28.2)
*p < 0.05 **p < 0.01 ***p < 0.001
∇ = BMD significantly better compared to LGMD2A;
X = BMD significantly better compared to LGMD2C-F
LGMD2C-F = Sarcoglycanopathies; BMD = Becker muscular dystrophy; LGMD2A = Calpaïnopathies
Table 4: Mean scores, SD's and differences by gender between adult patients and comparison group on the scales of the TAAQoL 
questionnaire
TAAQOL Males Females
mean (SD) mean (SD) mean (SD) mean (SD)
MD Healthy MD Healthy
N = 46 N = 1962 d N = 21 N = 2354 d
Gross Motor 34.6 (26.3)*** 88.2 (21.2) 2.5 29.5 (23.6)*** 83.7 (24.9) 2.2
Fine Motor 83.1 (20.8)*** 97.4 (10.4) 1.4 77.4 (16.9)*** 93.8 (16.0) 1.0
Cognitive 
Functioning
82.7 (24.4) 83.4 (22.0) 0.0 76.5 (29.8) 82.3 (23.4) 0.3
Sleeping 77.6 (32.1) 78.8 (24.1) 0.1 39.9 (36.4)** 69.8 (27.1) 1.1
Pain 69.4 (24.2)* 76.8 (22.9) 0.3 61.3 (33.7) 70.4 (25.0) 0.4
Social Functioning 89.5 (19.5) 84.8 (17.3) -0.3 91.4 (12.4)** 82.8 (20.7) -0.4
Daily activities 76.2 (31.4)* 85.8 (22.5) 0.4 65.2 (33.6)* 81.5 (26.5) 0.6
Sexual functioning 86.6 (30.4) 83.6 (27.7) -0.1 91.9 (15.9) 86.3 (23.6) -0.2
Vitality 53.6 (24.6)*** 68.0 (22.4) 0.6 43.3 (31.6)* 60.4 (24.7) 0.7
Happiness 67.6 (21.5) 65.2 (21.0) -0.1 60.3 (18.6) 64.1 (22.4) 0.2
Aggressiveness 78.7 (23.8)* 87.5 (17.2) 0.5 76.7 (26.5) 87.9 (16.4) 0.7
Depressive moods 72.3 (24.3)* 81.6 (19.2) 0.5 64.7 (21.9)* 75.0 (21.3) 0.5
One sample t-tests *p < 0.05 **p < 0.01 ***p < 0.001
d = effect size
Higher score represent a better HRQoLHealth and Quality of Life Outcomes 2007, 5:31 http://www.hqlo.com/content/5/1/31
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cancer [21]. Response shift implies that the experience
with an illness changes the internal standards of patients,
resulting in changes in the meaning of their self-evalua-
tion and hence in a possibly different experience of prob-
lems.
We did not find cognitive problems for the younger and
older children; nor in adults. It is important to notice that
children and adolescent do not report more negative emo-
tions compared to their healthy peers. Negative emotions
included in the questionnaire are feelings of irritation, or
anger. Adult patients, and especially males, however do
report negative emotions, e.g. feelings of aggressiveness.
For adult patients HRQoL was lower on several scales as
compared to the general population. Pain was reported,
only by males, but not associated with type or severity of
MD. This finding supports those of Abresch et al [22] who
studied the effect of pain on the QoL of individuals with
slowly progressive neuromuscular disease (NMD), includ-
ing a group of LGMD patients. They found that with the
exception of adult spinal muscular atrophy, the frequency
and severity of pain reported in slowly progressive NMDs
was significant.
Within-group differences were studied for the adult
patients. For type of MD we found a more favorable
HRQoL for BMD patients. Interindividual disease progres-
sion variation in BMD is extensive, and several of these
patients were only mildly affected. For severity only minor
differences were found, possibly explained by BMD
patients. Consequently, some confounding of type of MD
and severity should be taken into account.
Results of this study show that patients with more severe
disease do not necessarily have a worse HRQoL. Only dif-
ferences on fine motor and social functioning were found.
Apparently, severity is not a factor that significantly influ-
ences HRQoL. This is in line with findings of Abresch et al
[8] who also studied factors that influence HRQoL in
patients with neuromuscular diseases. They found that
level of disability is not a factor that significantly alters life
satisfaction. They postulate that this is because physical
functioning has been adequately managed by the patients.
Comparable findings are reported by Kohler et al. [23].
They report that quality of life is not correlated with phys-
ical impairment.
There are a few limitations to this study. Firstly, the study
has a relatively small sample size. Secondly, there is prob-
ably a selection bias. All patients who participate in this
study were participating already in another study. It is
most likely that this has positively influenced the
response rate. Thirdly, most assessments of the question-
naire were done by phone. It is not clear how this may
have influenced the responses. Fourth, only a restricted
number of predictors, namely severity and type of muscu-
lar dystrophy, could be investigated, and only in the adult
patient population. For example, use of medication such
as prednisone or other corticosteroids could also influ-
ence the HRQoL outcome. More longitudinal research is
needed to trace the patients, at risk for adjustment prob-
lems. An interesting area of research would be the coping
resources patients use, and preferably the research should
be conducted administering questionnaires to patients in
person and interviewing them. Furthermore, nearly all of
the children participating in this study were boys with
Duchenne muscular dystrophy. Therefore, the generaliza-
bility of this data to children with other forms of MD and
to girls does not seem valid.
Overall, it should be acknowledged that the findings for
adults only show a few large effect sizes on especially func-
tional domains (gross and fine motor functioning) and
for sleeping for females only. Moderate clinical differ-
ences are found for aggressiveness, depressive moods and
vitality. Communication about such problems in clinical
practice should be encouraged to evaluate in which way
the patient is troubled. This can be stimulated by compu-
ter-scored individually measurement of HRQoL, in order
to inform the physician about the patient's HRQoL
[24,25]. The computer output – usually a graphical sum-
mary of HRQoL outcomes – assists the physician to focus
at the HRQoL domains that correspond with patients
needs. Utilizing HRQoL measurement can facilitate
patient-physician communication and identifying
Table 6: Mean health-related quality of life scores for adults 
patients on the TAAQoL according to severity of MD
TAAQOL Severity
mean (SD) mean (SD)
Less severe Severe
N = 25 N = 42
Gross Motor 29.8 (25.7) 35.0 (25.4)
Fine Motor 95.3 (6.8)*** 73.0 (20.2)
Cognitive Functioning 79.0 (29.5) 81.8 (24.3)
Sleeping 70.8 (38.9) 62.8 (37.0)
Pain 65.0 (25.3) 68.0 (29.0)
Social Functioning 95.5 (11.2)* 86.9 (19.9)
Daily activities 76.0 (27.3) 70.8 (35.1)
Sexual functioning 91.1 (22.1) 86.5 (29.5)
Vitality 55.0 (26.2) 47.6 (27.6)
Happiness 68.7 (18.4) 63.3 (22.0)
Aggressiveness 73.8 (26.4) 80.7 (23.2)
Depressive moods 74.7 (20.1) 67.1 (25.4)
Student t-tests *p < 0.05 **p < 0.01 ***p < 0.001
Higher scores represent a better HRQoLHealth and Quality of Life Outcomes 2007, 5:31 http://www.hqlo.com/content/5/1/31
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patients with the greatest needs, so that referring to other
health care providers is possible.
Conclusion
In conclusion, this is one of he first studies to describe the
HRQoL of patients with MD using validated and reliable
instruments in different age groups. The results of the
present study indicate that having MD negatively influ-
ences HRQoL. Even though children and adult patients
are often considered resilient, HRQoL data show several
areas in which patients report difficulties. Clinical signifi-
cant differences are especially found for younger children.
We believe that children and adult patients should be
monitored carefully in order to provide additional sup-
port such as information, emotional and educational
guidance.
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